Drug Combination Details
| General Information of the Combination (ID: C64576) | |||||
|---|---|---|---|---|---|
| Name | Glycyrrhetinic acid NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | KDR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of Glycyrrhetinic acid as an angiogenesis inhibitor and Doxorubicin obtain the synergistic anticancer efficacy and reduce cardiotoxicity. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | Nude mice were subcutaneously inoculated with HepG2 cells at a density of 5 * 106 cells/mouse. | |||||
| Experimental
Result(s) |
DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo. | |||||
